Medpace (NASDAQ:MEDP) Announces Quarterly Earnings Results

Medpace (NASDAQ:MEDP) posted its quarterly earnings data on Wednesday. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54, FiscalAI reports. Medpace had a return on equity of 149.31% and a net margin of 17.19%.The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the business earned $3.67 EPS. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace updated its FY 2026 guidance to 16.680-17.500 EPS.

Medpace Price Performance

MEDP stock opened at $393.42 on Friday. The business has a 50 day simple moving average of $470.96 and a 200-day simple moving average of $536.55. The firm has a market capitalization of $11.24 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 2.39 and a beta of 1.39. Medpace has a 1 year low of $284.10 and a 1 year high of $628.92.

Analyst Ratings Changes

Several research firms have commented on MEDP. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Truist Financial dropped their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $486.67.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

A number of large investors have recently made changes to their positions in MEDP. NewEdge Advisors LLC grew its position in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new position in Medpace in the second quarter worth approximately $296,000. Finally, M&T Bank Corp grew its position in Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after acquiring an additional 31 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat on sales and earnings: Medpace posted $706.6M revenue (+26.5% YoY) and $4.28 GAAP EPS, each above consensus, showing continued top-line growth and margin strength. This supports the company’s long-term profitability thesis. Earnings Transcript
• Neutral Sentiment: Backlog conversion outlook vs. cancellations: Management said roughly $1.94B of backlog is expected to convert in the next 12 months — a positive indicator for near-term revenue — but also noted rising cancellations, which clouds forward visibility. Investors will watch conversion cadence closely. Backlog Conversion Article
• Neutral Sentiment: FY2026 guidance maintained but not clearly above street: Medpace maintained EPS guidance of $16.68–$17.50 and revenue near $2.8B–$2.9B; the EPS range slightly brackets consensus, leaving room for debate whether guidance is conservative or disappointing. Press Release
• Negative Sentiment: Booking weakness — book-to-bill below 1.0: Net new business awards were $618.4M in Q1, producing a net book-to-bill of ~0.88x, signaling bookings lagging billed revenue and stoking concerns about near-term demand sustainability. That was the primary driver of the sharp share decline. Investor Coverage of Booking Miss
• Negative Sentiment: Leadership change disclosed: The company disclosed President Jesse Geiger plans to retire effective May 31, 2026, with the CEO temporarily reassuming the role — an unexpected governance change that added to investor uncertainty. QuiverQuant Report
• Negative Sentiment: Multiple securities class-action notices filed: Several law firms have announced investigations and class-action filings tied to alleged misstatements about growth and bookings; potential litigation is a headline risk and could pressure sentiment. Class Action Notice Investor Deadline Notice

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.